Shares of Life Science REIT plc (LON:LABS - Get Free Report) traded up 0.8% on Friday . The stock traded as high as GBX 38.50 ($0.49) and last traded at GBX 38.50 ($0.49). 480,578 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 990,415 shares. The stock had previously closed at GBX 38.20 ($0.48).
Analyst Ratings Changes
A number of equities analysts have recently commented on LABS shares. Berenberg Bank reissued a "buy" rating and issued a GBX 57 ($0.72) price target on shares of Life Science REIT in a report on Thursday, October 3rd. Jefferies Financial Group cut their price objective on Life Science REIT from GBX 45 ($0.57) to GBX 36 ($0.45) and set a "hold" rating for the company in a report on Friday, August 30th. Finally, Shore Capital reaffirmed a "buy" rating on shares of Life Science REIT in a research note on Thursday, September 26th.
View Our Latest Research Report on LABS
Life Science REIT Stock Performance
The business has a 50 day moving average price of GBX 39.82 and a two-hundred day moving average price of GBX 36.12. The company has a market cap of £134.75 million, a P/E ratio of -641.67 and a beta of 0.08.
Life Science REIT Announces Dividend
The company also recently announced a dividend, which was paid on Thursday, October 31st. Stockholders of record on Thursday, October 3rd were issued a GBX 1 ($0.01) dividend. This represents a dividend yield of 3.11%. The ex-dividend date of this dividend was Thursday, October 3rd. Life Science REIT's dividend payout ratio is -3,333.33%.
Life Science REIT Company Profile
(
Get Free Report)
Life Science REIT plc (the Company) is a closed-ended Real Estate Investment Trust (REIT) incorporated in England and Wales on 27 July 2021. The Company began trading on 19 November 2021 and its shares are admitted to trading on the Premium Listing Segment of the Main Market of the London Stock Exchange.
Read More
Before you consider Life Science REIT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Life Science REIT wasn't on the list.
While Life Science REIT currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
